Tarsus Pharmaceuticals secures $125.0 million in oversubscribed Private Placement Equity Financing, led by Barclays with participation from TCGX and Bain Capital. The funds will support clinical development and corporate activities.
Vestal Point CapitalRtw InvestmentsSirenia Capital Management LPAdar1 Capital ManagementWellington ManagementBain Capital Life SciencesTcgx
Description
Tarsus Pharmaceuticals has entered into a securities purchase agreement for a $125.0 million PIPE financing, with participation from both existing and new investors. The financing includes the sale of common stock and pre-funded warrants. Funds will be used for clinical development and other corporate purposes. The deal is expected to close on August 7, 2026.
Company Information
Company
Tarsus Pharmaceuticals
Location
Irvine, California, United States
About
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
Fundz sees it the moment Tarsus Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
IrvineManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma